Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer Sheds Vicuron And Cholesterol Drug

by Lisa M. Jarvis
January 4, 2010 | A version of this story appeared in Volume 88, Issue 1

Pfizer has sold Vicuron Pharmaceuticals to Durata Therapeutics, an antibiotics-focused drug company recently formed by a five-member venture capital syndicate. Terms were not disclosed, but Pfizer paid $1.9 billion for Vicuron in 2005. Durata gains dalbavancin, a long-acting lipoglycopeptide in late-stage trials for treatment of bacterial infections of the skin and skin structure. Pfizer is keeping the antifungal Eraxis. Separately, Pfizer out-licensed ApoA-I Milano, a variant of apolipoprotein A-I that helps remove cholesterol from artery walls, to the Medicines Co. Pfizer gets $10 million up front for the drug and could receive another $410 million in milestones as it moves toward the market.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.